Stage C Heart Failure Management

Definition and Clinical Characteristics

Stage C heart failure encompasses patients with structural heart disease who are currently symptomatic or have a history of heart failure symptoms, corresponding to NYHA functional classes I through IV, according to the American Family Physician 1.

The American College of Cardiology recommends ACE inhibitors or ARBs as foundation therapy for all Stage C patients with reduced ejection fraction to prevent disease progression and reduce mortality 2.
Beta-blockers should be used in all Stage C patients with reduced ejection fraction to prevent symptomatic worsening and improve survival when combined with ACE inhibition, as recommended by the European Society of Cardiology 2.
Diuretics are essential for patients with evidence or history of fluid retention, providing symptomatic relief from volume overload and reducing congestive symptoms, according to the American Heart Association 1, 4, 5.
The European Society of Cardiology recommends SGLT2 inhibitors (dapagliflozin or empagliflozin) as foundational therapy for HFrEF to reduce heart failure hospitalizations and death 3.

The American Heart Association recommends ICD therapy for primary prevention of sudden cardiac death in selected HFrEF patients at least 40 days post-MI with LVEF ≤35% and NYHA class II or III symptoms on chronic GDMT, who are expected to live >1 year 4, 5, 3.
CRT is indicated for patients with LVEF ≤35%, sinus rhythm, and LBBB with QRS ≥150 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT, with Class I, Level A evidence from the American Heart Association 4, 5, 3.

The American Heart Association recommends exercise training or regular physical activity as safe and effective for Stage C patients who are able to participate, to improve functional status, with Class I, Level A evidence 6.

The European Society of Cardiology recommends enrollment in a multidisciplinary heart failure management program to reduce heart failure hospitalizations and improve survival, with a Class I, Level A recommendation 3.

The American College of Cardiology advises against using thiazolidinediones in patients with LVEF <50%, as they increase heart failure risk and hospitalizations 7.
Nondihydropyridine calcium channel blockers (diltiazem, verapamil) with negative inotropic effects should be avoided in patients with LVEF <50%, as they may be harmful, according to the American Heart Association 7.